EVFM Key Statistics, Chart & Performance
The current stock price of EVFM is 0.4782 USD. In the past month the price decreased by -58.42%. In the past year, price decreased by -95.52%.
EVFM Latest News, Press Relases and Analysis
EVFM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.19 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 19.64 | 491.06B | ||
| MRK | MERCK & CO. INC. | 11.1 | 244.18B | ||
| PFE | PFIZER INC | 7.82 | 142.37B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.05 | 94.14B | ||
| ZTS | ZOETIS INC | 19.25 | 54.09B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.47 | 22.70B | ||
| VTRS | VIATRIS INC | 4.49 | 12.20B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.18 | 11.05B | ||
| CORT | CORCEPT THERAPEUTICS INC | 87.83 | 8.13B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.46B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.21B |
Related stock screener links
About EVFM
Company Profile
Evofem Biosciences Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in San Diego, California and currently employs 119 full-time employees. The company went IPO on 2014-11-20. Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The company is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. The company also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.
Company Info
EVOFEM BIOSCIENCES INC
12400 High Bluff Dr Ste 600
San Diego CALIFORNIA 92130 US
CEO: Saundra Pelletier
Employees: 119
Phone: 18585501900.0
EVOFEM BIOSCIENCES INC / EVFM FAQ
Can you describe the business of EVOFEM BIOSCIENCES INC?
Evofem Biosciences Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in San Diego, California and currently employs 119 full-time employees. The company went IPO on 2014-11-20. Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The company is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. The company also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.
What is the stock price of EVOFEM BIOSCIENCES INC today?
The current stock price of EVFM is 0.4782 USD. The price decreased by -23.37% in the last trading session.
Does EVOFEM BIOSCIENCES INC pay dividends?
EVFM does not pay a dividend.
What is the ChartMill technical and fundamental rating of EVFM stock?
EVFM has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does EVOFEM BIOSCIENCES INC belong to?
EVOFEM BIOSCIENCES INC (EVFM) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the market cap for EVOFEM BIOSCIENCES INC?
EVOFEM BIOSCIENCES INC (EVFM) has a market capitalization of 20.18M USD. This makes EVFM a Nano Cap stock.
What is the Short Interest ratio of EVOFEM BIOSCIENCES INC (EVFM) stock?
The outstanding short interest for EVOFEM BIOSCIENCES INC (EVFM) is 0.07% of its float.
EVFM Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to EVFM. When comparing the yearly performance of all stocks, EVFM is a bad performer in the overall market: 98.86% of all stocks are doing better.
EVFM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EVFM. Both the profitability and financial health of EVFM have multiple concerns.
EVFM Financial Highlights
Over the last trailing twelve months EVFM reported a non-GAAP Earnings per Share(EPS) of -15.3. The EPS decreased by -553.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1676.29% | ||
| ROA | -552.28% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
EVFM Forecast & Estimates
11 analysts have analysed EVFM and the average price target is 11.27 USD. This implies a price increase of 2256.96% is expected in the next year compared to the current price of 0.4782.
For the next year, analysts expect an EPS growth of 57.85% and a revenue growth 295.01% for EVFM